Case Report: A novel MET exon 14 skipping mutation after EGFR-TKI resistance in advanced lung adenocarcinoma and sustained clinical response to savolitinib

BackgroundThe MET proto-oncogene (MET) plays a crucial role as an oncogenic driver gene in non-small cell lung cancer (NSCLC). At present, numerous types of MET exon 14 (METex14) skipping mutation have been identified, but different splice variants often exhibit varying treatment responses. There is...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Yinyin Xue, Wen Li, Pengfei Li, Kaili Huang, Qinghua Zhou, Qiang Wu
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2025-03-01
Serie:	Frontiers in Pharmacology
Soggetti:	novel MET exon 14 skipping mutation EGFR-TKI resistance advanced lung adenocarcinoma savolitinib sustained clinical response
Accesso online:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1489696/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!